Nomogram may predict readmission within 6 months after treatment in ACS patients

Written By :  Dr. Kamal Kant Kohli
Published On 2022-11-15 06:00 GMT   |   Update On 2022-11-15 07:15 GMT

CHINA: In a study published in BMC Cardiovascular Disorders, a nomogram prediction model was designed and internally verified to predict patient readmission within six months of acute coronary syndrome.A significant factor in cardiovascular disease-related deaths is ACS. In ACS patients, readmission is a frequent, expensive, and avoidable adverse event. Early readmission is still a...

Login or Register to read the full article

CHINA: In a study published in BMC Cardiovascular Disorders, a nomogram prediction model was designed and internally verified to predict patient readmission within six months of acute coronary syndrome.

A significant factor in cardiovascular disease-related deaths is ACS. In ACS patients, readmission is a frequent, expensive, and avoidable adverse event. Early readmission is still a regular occurrence, which greatly increases the financial burden on patients and adversely impacts their quality of life, even if the survival rate of ACS patients following hospitalization has increased.

Ke Li, Department of Cardiology, Hainan Hospital of Chinese People's Liberation Army General Hospital and team noted that "it is crucial to investigate and identify these individuals who are at risk of readmission as well as the predictors linked with readmission in order to implement proactive secondary prevention measures to decrease ACS readmissions, improve short- and long-term outcomes, and lessen economic burden."

The researchers sought to investigate the factors that influence readmission in ACS patients within six months, to create a prediction model, and to produce a nomogram

A retrospective cohort analysis involving 498 ACS patients treated at the Chinese People's Liberation Army General Hospital's Second Medical Center between January 2016 and March 2019 was carried out. To look at variables for readmission within six months, univariate and multivariate logistic regression with odds ratios (OR) and two-sided 95% confidence interval (CI) analyses were performed. The cohort was randomly split into a training cohort and a validation cohort in order to construct a prediction model and validate the model. To evaluate discriminative power and calibration, the receiver operating characteristic curve (ROC) and calibration curve were utilized.

Conclusive points of the study:

  • A 16.67% readmission rate for 83 ACS patients who were readmitted within six months.
  • To create a six-month readmission prediction model for ACS patients, predictors such as ACS type, therapy, hypertension, SUA, length of stay, statins, and adverse events experienced during hospitalization were considered.
  • In the training cohort and the validation cohort, the model's area under the curve (AUC) was 0.788 (95% CI: 0.735-0.878) and 0.775 (95% CI: 0.686-0.865), respectively.
  • The prediction model's calibration was satisfactory, as evidenced by the calibration curves.
  • Its therapeutic usefulness was further shown by decision-curve analysis and a clinical impact curve.

"Our nomogram demonstrated high predictive performance, which could assist clinicians in early patient identification and management of patients who require active attention and regular follow-up," the authors concluded.

Finding modifiable determinants of ACS readmission could lead to the development of preventative measures that enhance patient outcomes and lower medical expenses, they added.

REFERENCE

Li, D., Lin, Y., Dong, W. et al. A nomogram for predicting the readmission within 6 months after treatment in patients with acute coronary syndrome. BMC Cardiovasc Disord 22, 448 (2022). https://doi.org/10.1186/s12872-022-02873-6

 

Tags:    
Article Source : BMC Cardiovascular Disorders

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News